Mission Pharmacal Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Antonio TX United States (1946)

Organization Overview

First Clinical Trial
2005
NCT00229216
First Marketed Drug
1971
urea
First NDA Approval
1983
acetohydroxamic acid
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MISSION PHARMA | MISSION PHARMACAL | MISSION PHARMACAL CO

Active Ingredients

Marketed Drugs (13)

acetohydroxamic acid (1983 NDA)

alendronic acid (fosamax) (2012)

carbinoxamine maleate (clistin) (2011)

cellulose (1982)

folic acid (1981)

gabapentin (neurontin) (2011)

homatropine (1979)

potassium citrate (urocit-k) (1985 NDA)

potassium iodide (thyro-block) (2016)

prednisolone (hydeltra) (2010)

tinidazole (tindamax) (2004)

tiopronin (thiola) (1988 NDA)

urea (1971)

Drugs in Phase 3 Trials (1)

tinidazole (tindamax) (2 trials)

Drugs in Phase 2 Trials (2)

cow milk (1 trial)

mpc-5971 (1 trial)

Indications

Approved Indications


 

Cystinuria

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 2)

Kidney Calculi (Phase 2)

Nephrolithiasis (Phase 2)

Urinary Tract Infections (Phase 2)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3